pharma · CXCR4 · Uterine Cervical Neoplasms
Zhongnan Hospital drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zhongnan Hospital drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Development asset linked to Zhongnan Hospital in public FDA and regional records. Molecular target: Platelet-derived growth factor receptor beta.
Development asset linked to Zhongnan Hospital in public FDA and regional records.
Development asset linked to Zhongnan Hospital in public FDA and regional records.
Development asset linked to Zhongnan Hospital in public FDA and regional records.
US regulatory status: approved.